The drug works by mimicking the effects of GLP-1 and hitting receptors for another hormone, GIP, which leads to even more weight loss
Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity
Comorbidities diabetes, heart disease, or fatty liver disease may influence drug choice
The GLP-1 receptor agonists cardiovascular benefits are believed to stem from their effects in reducing dysfunctional body fat cells, improving glycemic control, reducing blood pressure and inflammation, and perhaps improving vascular endothelial function and plaque stability
Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
"We might find some real problems if we are not monitoring the body composition, especially for the older patients," Ahmed says